Beam Therapeutics Inc. Shareholders' Equity
Beam Therapeutics Inc. (BEAM) had Shareholders' Equity of $1.07 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.07B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.16B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.24B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $966.00M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.07B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.16B 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $1.24B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $966.00M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.05B 10-Q · filed 2026-08-04 | $1.05B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.13B 10-Q · filed 2026-08-04 | $1.12B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $733.54M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $791.32M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $854.09M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $913.49M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $981.33M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $778.94M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $811.64M 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $761.51M 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $733.47M 10-K · filed 2026-02-24 | |
| 2022-09-30 | $714.48M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $800.16M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $829.07M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $826.74M 10-K · filed 2025-02-25 | |
| 2021-09-30 | $853.81M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $548.55M 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $422.43M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $245.56M 10-K · filed 2024-02-27 | |
| 2020-09-30 | $200.07M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $230.82M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $261.39M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | -$201.10M 10-K · filed 2023-02-28 | |
| 2019-09-30 | -$172.06M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$151.87M 10-Q · filed 2020-11-10 | |
| 2019-03-31 | -$132.99M 10-Q · filed 2020-11-10 | |
| 2018-12-31 | -$117.41M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |